Ophthalmology Perspectives | Ep 3 | Gene Therapy, Patient-Centric Operations, and Risk-Benefit Challenges in Phase 1 Ophthalmology Trials episode artwork

EPISODE · Feb 4, 2026 · 30 MIN

Ophthalmology Perspectives | Ep 3 | Gene Therapy, Patient-Centric Operations, and Risk-Benefit Challenges in Phase 1 Ophthalmology Trials

from The Fortrea Podcast · host Marina

Today we explore the unique challenges and opportunities in Phase 1 ophthalmology clinical trials, focusing on gene therapy and inherited retinal diseases. Host: Amber BurgParticipants: David Hoelscher, Senior Medical Director, Ophthalmology Tanya Richardson, Therapeutic Strategy Head, Ophthalmology and Neuroscience 

Today we explore the unique challenges and opportunities in Phase 1 ophthalmology clinical trials, focusing on gene therapy and inherited retinal diseases. Host: Amber Burg Participants: David Hoelscher, Senior Medical Director, Ophthalmology Tanya Richardson, Therapeutic Strategy Head, Ophthalmology and Neuroscience

NOW PLAYING

Ophthalmology Perspectives | Ep 3 | Gene Therapy, Patient-Centric Operations, and Risk-Benefit Challenges in Phase 1 Ophthalmology Trials

0:00 30:45

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Fortrea Podcast?

This episode is 30 minutes long.

When was this The Fortrea Podcast episode published?

This episode was published on February 4, 2026.

What is this episode about?

Today we explore the unique challenges and opportunities in Phase 1 ophthalmology clinical trials, focusing on gene therapy and inherited retinal diseases. Host: Amber BurgParticipants: David Hoelscher, Senior Medical Director, Ophthalmology Tanya...

Can I download this The Fortrea Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!